WOW got an answer from Juan Vera:
Dear Dennis,
Thank you for your question and your ongoing interest in our company.
The press release issued on June 12 on the first lymphoma patient treated with MT-601 in the company sponsored Phase 1 clinical trial was indeed an important milestone for us, and we understand the excitement and curiosity it has sparked among our shareholders.
While it’s an important part, it's not the entirety of the strategic restructuring of our clinical programs that we alluded to in the video interview with Proactive in May. This particular announcement, which promises a comprehensive view of the restructuring of our clinical program, is still forthcoming.
The strategic review and restructuring of our clinical programs is a comprehensive process. It's not about one single program or research direction, but rather a holistic reconsideration of how our clinical programs are developed and carried out. This review is designed to increase efficiency, foster innovation, and improve results across all areas of our work. We are currently in the final stages of preparing this comprehensive review and plan to present it in late July/early August.
We understand our shareholders’ eagerness to learn more about our strategic developments and the future direction of Marker Therapeutics. Please be assured that we are working diligently to provide clear, comprehensive and timely information, and we are looking forward to sharing more about our exciting new directions in the coming weeks.We remain committed to our mission of improving patient care through innovative immunotherapies, and we greatly appreciate your continued support and patience.
Best regards,
Juan
